Skip to main content

PREDICCION DE ENFERMEDAD RESIDUAL DESPUES DE LA TERAPIA NEOADYUVANTE EN CANCER DE MAMA HER2 POSITIVO E IDENTIFICACION DE ESTRATEGIAS PARA SUPERAR LA RESISTENCIA

PI21/00002

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2021
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO HOSPITAL DEL MAR DE INVESTIGACIONES MEDICAS (FIMIM)
Execution centre INSTITUTO HOSPITAL DEL MAR DE INVESTIGACIONES MEDICAS (IMIM)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Enhancing immunotherapy through -1 upregulation, the promising combination of anti--1 plus m inhibitors

  • Hernández-Prat, Anna|||0000-0002-8233-1035
  • Rodriguez-Vida, Alejo|||0000-0002-7304-6857
  • Cardona, Laura
  • Qin, Mengjuan|||0000-0001-7014-7188
  • Arpí-Llucià, Oriol
  • Soria-Jiménez, Luis|||0000-0002-2182-8953
  • Menéndez, Sílvia|||0000-0002-9116-8743
  • Quimis, Fabricio Gerel
  • Galindo, Miguel
  • Arriola, Edurne|||0000-0001-8960-7519
  • Salido, Marta|||0000-0001-9988-5977
  • Juanpere-Rodero, Nuria
  • Rojo, Federico|||0000-0001-9989-0290
  • Muntasell i Castellví, Aura|||0000-0003-2894-0486
  • Albanell Mestres, Joan|||0000-0003-1239-4580
  • Rovira, Ana|||0000-0003-1301-2599
  • Bellmunt, Joaquim|||0000-0003-2328-3421
Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) pathway have transformed urothelial cancer (UC) therapy. The correlation between PD-L1 expression and ICI effectiveness is uncertain, leaving the role of PD-L1 as a predictive marker for ICI efficacy unclear. Among several ways to enhance the efficacy of ICI, trials are exploring combining ICIs with serine/threonine-protein kinase mTOR (mTOR) inhibitors in different tumor types. The potential interaction between mTOR inhibitors and PD-L1 expression in UC has not been well characterized. In our study, we investigated how phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway inhibitors (TAK-228, everolimus and TAK-117) affect PD-L1 expression and function in preclinical bladder cancer cell models. TAK-228 increased cell surface levels of glycosylated PD-L1 in all but one of the seven cell lines, regardless of baseline levels. TAK-228 promoted the secretion of epidermal growth factor (EGF) and interferon-β (IFNβ), both linked to PD-L1 protein induction. Blocking EGF and IFNβ receptors reversed the TAK-228-induced PD-L1 increase. Additionally, TAK-228 enhanced IFN-γ-induced PD-L1 expression and intracellular HLA-I levels in some cells. TAK-228-treated bladder cancer cells exhibited resistance to the cytotoxic effects of peripheral blood mononuclear cells (PBMCs) and cluster of differentiation 8 (CD8)+ T cells. The addition of an anti-PD-L1 antibody diminished this resistance in T24 cells. Increased expression of PD-L1 under TAK-228 exposure was confirmed in patient-derived explants (PDEs) treated ex vivo. These preclinical findings suggest that mTOR inhibition with TAK-228 can increase PD-L1 levels, potentially impacting the specific immune response against UC cells. This highlights the rationale for exploring the combination of mTOR inhibitors with ICIs in patients with advanced UC. mTOR inhibition with TAK-228 can increase PD-L1 levels, potentially impacting the specific immune response against bladder cancer cell lines.